← ANALYST RATINGS · TIPRANKS
Foghorn Therapeutics (FHTX): analyst forecast and price target
Analyst consensus
Moderate Buy4 Buy5 Hold0 Sell
Ratings of 9 analysts in the last 3 months12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $5.00, the highest $10.00, the lowest $2.00. The average is +170.3% from the last price of $1.85.
Analyst ratings 18
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $14.00 → $3.00−78.6% | Hold | +62.2% | Downgrade | 12.10.26on TipRanks Oct 13 05:25 | −2.4%next day −5.1% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 → $2.00−33.3% | Sell | +8.1% | Downgrade | 03.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Sell | +8.1% | Reiterated | 03.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.00 → $2.00−33.3% | Hold | +8.1% | Reiterated | 03.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 → $2.00−33.3% | Hold | +8.1% | Upgrade | 03.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $2.00−42.9% | Sell | +8.1% | Reiterated | 03.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 → $2.00−33.3% | Hold | +8.1% | Reiterated | 03.10.26on TipRanks 06:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | +62.2% | Reiterated | 02.10.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $2.50−28.6% | Sell | +35.1% | Reiterated | 02.10.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | +62.2% | Reiterated | 02.10.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Sell | +62.2% | Downgrade | 02.10.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | +62.2% | Reiterated | 02.10.26on TipRanks 12:05 | — | |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $10.00 → $2.00−80.0% | Hold | +8.1% | Downgrade | 02.10.26on TipRanks 06:55 | −31.6%next day −1.7% · 5 days −2.2% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $13.00 → $5.00−61.5% | Buy | +170.3% | Reiterated | 02.10.26on TipRanks 06:20 | −31.6%next day −1.7% · 5 days −2.2% | ↗ |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $3.50−12.5% | Sell | +89.2% | Downgrade | 02.10.26on TipRanks 00:05 | — | |
| Unknown Analyst | Guggenheim | $12.00 → $5.00−58.3% | Buy | +170.3% | Reiterated | 01.10.26on TipRanks Oct 2 08:30 | −18.4%next day −31.6% · 5 days −33.2% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | — | Hold | — | Downgrade | 01.10.26on TipRanks 16:45 | −31.6%next day −1.7% · 5 days −2.2% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | — | Hold | — | Downgrade | 01.10.26on TipRanks 16:30 | −31.6%next day −1.7% · 5 days −2.2% | ↗ |
| Silvan Tuerkcan★★★★★★★★★★#731 · hits 43% · avg +16.6% | Citizens JMP | — | Hold | — | Downgrade | 01.10.26on TipRanks 14:55 | −18.4%next day −31.6% · 5 days −33.2% | ↗ |
| Laura Prendergast★★★★★★★★★★#345 · hits 76% · avg +52.4% | Stifel Nicolaus | $12.00 → $5.00−58.3% | Buy | +170.3% | Reiterated | 01.10.26on TipRanks 13:10 | −18.4%next day −31.6% · 5 days −33.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $3.50−12.5% | Hold | +89.2% | Reiterated | 01.10.26on TipRanks 12:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.50 → $4.00−11.1% | Hold | +116.2% | Reiterated | 24.09.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.50−12.5% | Sell | +89.2% | Downgrade | 24.09.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | +89.2% | Reiterated | 24.09.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $3.50−12.5% | Hold | +89.2% | Upgrade | 24.09.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 | Hold | +116.2% | Reiterated | 24.09.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | +89.2% | Reiterated | 24.09.26on TipRanks 06:05 | — | |
| Unknown Analyst | B. Riley Securities | $10.00 | Buy | +440.5% | Initiated | 27.08.26on TipRanks Sep 3 21:10 | −7.7%next day −3.3% · 5 days −22.0% | ↗ |
| Laura Prendergast★★★★★★★★★★#345 · hits 76% · avg +52.4% | Stifel Nicolaus | $12.00 | Buy | +548.6% | Reiterated | 17.08.26on TipRanks 07:20 | +8.1%next day +0.8% · 5 days +3.1% | ↗ |
| Unknown Analyst | Evercore ISI | $14.00 | Buy | +656.8% | Reiterated | 10.08.26on TipRanks Aug 11 05:05 | +2.8%next day +5.9% · 5 days +8.1% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $13.00 | Buy | +602.7% | Reiterated | 07.08.26on TipRanks 06:50 | +8.4%next day +2.8% · 5 days +2.7% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $11.00 | Buy | +494.6% | Reiterated | 06.08.26on TipRanks Aug 7 07:10 | +14.3%next day +8.4% · 5 days +15.3% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $10.00 | Buy | +440.5% | Reiterated | 20.07.26on TipRanks Jul 24 05:11 | +0.2%next day −1.4% · 5 days +0.6% | ↗ |
| Unknown Analyst | Guggenheim | $12.00 | Buy | +548.6% | Reiterated | 07.05.26on TipRanks May 8 08:40 | −9.9%next day +4.9% · 5 days −6.1% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | — | Buy | — | Reiterated | 07.05.26on TipRanks 15:05 | −9.9%next day +4.9% · 5 days −6.1% | ↗ |
| Amin Makarem★★★★★★★★★★#7369 · hits 50% · avg +43.4% | Jefferies | $12.00 | Buy | +548.6% | Reiterated | 16.02.26on TipRanks Feb 17 21:22 | 0.0%next day +1.3% · 5 days +1.3% | ↗ |
| Silvan Tuerkcan★★★★★★★★★★#731 · hits 43% · avg +16.6% | Citizens JMP | $9.00 | Buy | +386.5% | Reiterated | 31.10.25on TipRanks 03:32 | +2.0%next day −4.7% · 5 days +0.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Foghorn Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $10.40 at a price of $3.57 (+191.3%); now: $5.00 at $1.85 (+170.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 6 | 5 | 7 | 6 | 8 |
| Buy | 2 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.25 (from $-0.41 to $-0.15). Last quarter: $-0.10.
Sales
Next quarter’s sales estimate — $6M (from $0M to $12M). Last quarter: $16M.
Best top-analyst consensus in the sector · Healthcare
About Foghorn Therapeutics
- CEO: Adrian H. Gottschalk
- Employees: 106
- 99 Coolidge Avenue, Watertown, MA, 02472, US
- foghorntx.com
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 44 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗